Veraxa Biotech Holding AG (VRXA) Stock Analysis

What Veraxa Biotech Holding AG does

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

Key metrics

ETFs linked to VRXA

Broad-market and Healthcare sector ETFs an investor holding Veraxa Biotech Holding AG is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VRXA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Veraxa Biotech Holding AG?

Veraxa Biotech Holding AG trades under the ticker VRXA on NASDAQ.

Which exchange is VRXA listed on?

VRXA is listed on NASDAQ.

What sector does Veraxa Biotech Holding AG operate in?

Veraxa Biotech Holding AG is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VRXA in a portfolio?

PortView shows VRXA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.